(Celecoxib + ciprofloxacin) is under clinical development by NeuroSense Therapeutics and currently in Phase II for Alzheimer’s Disease. According to GlobalData, Phase II drugs for Alzheimer’s Disease have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how (Celecoxib + ciprofloxacin)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Celecoxib + ciprofloxacin) overview
PrimeC is a fixed dose combination drug of celecoxib and ciprofloxacin. The therapeutic candidate is under development for the treatment of amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. It is an extended release formulation administered through oral route in the form of capsule and tablet. It acts by targeting DICER gene and COX -2.
NeuroSense Therapeutics overview
NeuroSense Therapeutics is a biopharmaceutical company that discovers and develops novel therapeutics for the treatment of neurodegenerative diseases. The company is investigating PrimeC, a novel formulation composed of ciprofloxacin and celecoxib to treat amyotrophic lateral sclerosis (ALS). It is also developing novel therapeutics for alzheimer’s and parkinson’s diseases. NeuroSense Therapeutics conducts research and study mechanisms in targeting neurodegenerative diseases. The company has an operational presence in the US. NeuroSense Therapeutics is headquartered in Herzliya, Israel.
For a complete picture of (Celecoxib + ciprofloxacin)’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
